| Name | Title | Contact Details |
|---|
WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.
Fairmont General Hospital is a private, non-profit, community hospital founded in 1939. The hospital provides a wide variety of patient services and is accredited by the Joint Commission and the American College of Surgeons Commission on Cancer.
For people with life-threatening blood cancers like leukemia and lymphoma or other diseases, a cure exists. Be The Match connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant. Every year, thousands of men, women and children get life-threatening diseases like leukemia and lymphoma. Many of them will die unless they get a bone marrow or cord blood transplant from a genetically matched donor. Some people find a match in their family, but 70% do not. These patients depend on the Be The Match to help them find an unrelated donor or cord blood unit. Whether you want to swab your cheek and join Be The Match Registry, make a financial gift or download a photo to show your support on Facebook, you’re in the right place. The best part? Every action you take helps. Be The Match, operated by National Marrow Donor Program (NMDP), is a nonprofit organization dedicated to creating an opportunity for all patients to receive the marrow or umbilical cord blood transplant they need, when they need it.
Medical Practice Management Inc is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.